Efficacy and safety of sacituzumab govitecan in HR+/HER2– advanced breast cancer: A comprehensive systematic review and meta-analysis.

IF 2 3区 工程技术 Q3 CHEMISTRY, MULTIDISCIPLINARY Journal of Chemical & Engineering Data Pub Date : 2024-06-01 DOI:10.1200/jco.2024.42.16_suppl.e13085
Zaheer Qureshi, Abdur Jamil, Faryal Altaf, Rimsha Siddique
{"title":"Efficacy and safety of sacituzumab govitecan in HR+/HER2– advanced breast cancer: A comprehensive systematic review and meta-analysis.","authors":"Zaheer Qureshi, Abdur Jamil, Faryal Altaf, Rimsha Siddique","doi":"10.1200/jco.2024.42.16_suppl.e13085","DOIUrl":null,"url":null,"abstract":"e13085 Background: Breast cancer is the most commonly diagnosed cancer in women, with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) being the predominant subtype. Sacituzumab govitecan, a novel antibody-drug conjugate, has emerged as a promising treatment for metastatic HR+/HER2– breast cancer. The aim of this systematic review and meta-analysis was to evaluate its efficacy and safety. Methods: Adhering to PRISMA guidelines, a comprehensive search was conducted in PubMed, Scopus, and Cochrane databases up to December 2023. We included clinical trials and observational studies evaluating sacituzumab govitecan in patients with HR +/HER2–advanced breast cancer. The primary outcome was progression-free survival (PFS), while the secondary outcomes included overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), duration of response (DOR), and adverse event profiles. Various statistical models were used for the analysis. Results: Nine studies met the inclusion criteria, and three were suitable for meta-analysis. The pooled analysis showed a Hazard Ratio (HR) of 0.57 for PFS, indicating a significant reduction in disease progression, and an HR of 0.68 for OS, suggesting improved survival. The treatment also significantly increased the likelihood of tumor response and clinical benefit but was associated with a higher occurrence of adverse events. Conclusions: Sacituzumab govitecan demonstrated significant efficacy in treating HR+/HER2– advanced breast cancer, reducing disease progression and mortality. However, its use is associated with a high rate of adverse events. These findings highlight the potential of Sacituzumab govitecan as a valuable addition to breast cancer treatment regimens, warranting further investigation and long-term studies.","PeriodicalId":42,"journal":{"name":"Journal of Chemical & Engineering Data","volume":"130 18","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemical & Engineering Data","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/jco.2024.42.16_suppl.e13085","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

e13085 Background: Breast cancer is the most commonly diagnosed cancer in women, with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) being the predominant subtype. Sacituzumab govitecan, a novel antibody-drug conjugate, has emerged as a promising treatment for metastatic HR+/HER2– breast cancer. The aim of this systematic review and meta-analysis was to evaluate its efficacy and safety. Methods: Adhering to PRISMA guidelines, a comprehensive search was conducted in PubMed, Scopus, and Cochrane databases up to December 2023. We included clinical trials and observational studies evaluating sacituzumab govitecan in patients with HR +/HER2–advanced breast cancer. The primary outcome was progression-free survival (PFS), while the secondary outcomes included overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), duration of response (DOR), and adverse event profiles. Various statistical models were used for the analysis. Results: Nine studies met the inclusion criteria, and three were suitable for meta-analysis. The pooled analysis showed a Hazard Ratio (HR) of 0.57 for PFS, indicating a significant reduction in disease progression, and an HR of 0.68 for OS, suggesting improved survival. The treatment also significantly increased the likelihood of tumor response and clinical benefit but was associated with a higher occurrence of adverse events. Conclusions: Sacituzumab govitecan demonstrated significant efficacy in treating HR+/HER2– advanced breast cancer, reducing disease progression and mortality. However, its use is associated with a high rate of adverse events. These findings highlight the potential of Sacituzumab govitecan as a valuable addition to breast cancer treatment regimens, warranting further investigation and long-term studies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
萨希珠单抗戈维替康对HR+/HER2-晚期乳腺癌的疗效和安全性:全面系统综述和荟萃分析。
e13085 背景:乳腺癌是女性最常确诊的癌症,其中激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)是最主要的亚型。萨妥珠单抗戈维替康是一种新型抗体-药物共轭物,已成为治疗转移性HR+/HER2-乳腺癌的一种很有前景的方法。本系统综述和荟萃分析旨在评估其疗效和安全性。研究方法根据 PRISMA 指南,我们在 PubMed、Scopus 和 Cochrane 数据库中进行了全面检索,检索期截至 2023 年 12 月。我们纳入了对HR+/HER2-晚期乳腺癌患者进行评估的临床试验和观察性研究。主要结果是无进展生存期(PFS),次要结果包括总生存期(OS)、客观反应率(ORR)、临床获益率(CBR)、反应持续时间(DOR)和不良事件概况。分析中使用了多种统计模型。结果九项研究符合纳入标准,其中三项适合进行荟萃分析。汇总分析显示,PFS 的危险比(HR)为 0.57,表明疾病进展显著减少;OS 的危险比为 0.68,表明生存率提高。该疗法还能明显增加肿瘤反应和临床获益的可能性,但与不良反应发生率较高有关。结论萨妥珠单抗戈维替康治疗HR+/HER2-晚期乳腺癌疗效显著,可降低疾病进展和死亡率。然而,其使用与较高的不良事件发生率相关。这些发现凸显了萨妥珠单抗戈维替康作为乳腺癌治疗方案重要补充的潜力,值得进一步调查和长期研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Chemical & Engineering Data
Journal of Chemical & Engineering Data 工程技术-工程:化工
CiteScore
5.20
自引率
19.20%
发文量
324
审稿时长
2.2 months
期刊介绍: The Journal of Chemical & Engineering Data is a monthly journal devoted to the publication of data obtained from both experiment and computation, which are viewed as complementary. It is the only American Chemical Society journal primarily concerned with articles containing data on the phase behavior and the physical, thermodynamic, and transport properties of well-defined materials, including complex mixtures of known compositions. While environmental and biological samples are of interest, their compositions must be known and reproducible. As a result, adsorption on natural product materials does not generally fit within the scope of Journal of Chemical & Engineering Data.
期刊最新文献
Issue Publication Information Issue Editorial Masthead Insights into Molecular Interactions in Binary and Ternary Mixtures of Propan-1-ol, Pyridine, and Benzene: An Experimental and Modeling Approach Solid-Liquid Equilibrium Solubility Determination and Correlation of 5-Hydroxy-1-methylpyrazole in 12 Kinds of Pure Solvents Phase Behavior and Microscopic Mechanisms of Separation of n-Hexane and Methylcyclopentane Mixtures with Deep Eutectic Solvents
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1